These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30036346)

  • 21. Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification.
    Buntwal N; Bearn J; Gossop M; Strang J
    Drug Alcohol Depend; 2000 May; 59(2):183-8. PubMed ID: 10891632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal.
    Mannelli P; Peindl K; Wu LT; Patkar AA; Gorelick DA
    Am J Drug Alcohol Abuse; 2012 May; 38(3):200-5. PubMed ID: 22233189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lofexidine versus clonidine for mitigation of opioid withdrawal symptoms: A systematic review.
    Kuszmaul AK; Palmer EC; Frederick EK
    J Am Pharm Assoc (2003); 2020; 60(1):145-152. PubMed ID: 31791720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.
    Ziedonis DM; Amass L; Steinberg M; Woody G; Krejci J; Annon JJ; Cohen AJ; Waite-O'Brien N; Stine SM; McCarty D; Reid MS; Brown LS; Maslansky R; Winhusen T; Babcock D; Brigham G; Muir J; Orr D; Buchan BJ; Horton T; Ling W
    Drug Alcohol Depend; 2009 Jan; 99(1-3):28-36. PubMed ID: 18805656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.
    Strang J; Bearn J; Gossop M
    Am J Addict; 1999; 8(4):337-48. PubMed ID: 10598217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002025. PubMed ID: 15495026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detoxification and treating opioid dependence.
    de Jong CJ
    JAMA; 2006 Feb; 295(8):887; author reply 887-8. PubMed ID: 16493098
    [No Abstract]   [Full Text] [Related]  

  • 29. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine.
    White R; Alcorn R; Feinmann C
    Drug Alcohol Depend; 2001 Dec; 65(1):77-83. PubMed ID: 11714592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodynamic and cognitive effects of lofexidine and methadone coadministration: a pilot study.
    Schroeder JR; Schmittner J; Bleiberg J; Epstein DH; Krantz MJ; Preston KL
    Pharmacotherapy; 2007 Aug; 27(8):1111-9. PubMed ID: 17655511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Buprenorphine for the management of opioid withdrawal.
    Gowing L; Ali R; White J
    Cochrane Database Syst Rev; 2006 Apr; (2):CD002025. PubMed ID: 16625553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
    Sinha R; Kimmerling A; Doebrick C; Kosten TR
    Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal.
    Lin SK; Strang J; Su LW; Tsai CJ; Hu WH
    Drug Alcohol Depend; 1997 Nov; 48(2):127-33. PubMed ID: 9363412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha2-adrenergic agonists in opioid withdrawal.
    Gowing LR; Farrell M; Ali RL; White JM
    Addiction; 2002 Jan; 97(1):49-58. PubMed ID: 11895270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detoxification and treating opioid dependence.
    Contreras JA
    JAMA; 2006 Feb; 295(8):886-7; author reply 887-8. PubMed ID: 16493097
    [No Abstract]   [Full Text] [Related]  

  • 38. New directions in the treatment of opioid withdrawal.
    Srivastava AB; Mariani JJ; Levin FR
    Lancet; 2020 Jun; 395(10241):1938-1948. PubMed ID: 32563380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid antagonists with minimal sedation for opioid withdrawal.
    Gowing L; Ali R; White JM
    Cochrane Database Syst Rev; 2009 Oct; (4):CD002021. PubMed ID: 19821290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods of detoxification and their role in treating patients with opioid dependence.
    O'Connor PG
    JAMA; 2005 Aug; 294(8):961-3. PubMed ID: 16118388
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.